米氮平与马普替林治疗难治性抑郁症对照观察  

A comparative study of mirtazapine and maprotiline in the treatment of treatment - resistant depression

作　　者：丁国安[1] 余国汉[1] 黄鹏[1] 梁绍材[1] 何广贤[1] 

机构地区：[1]广州市精神病医院,广东广州510370

出　　处：《中国民康医学》2004年第4期193-195,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:评价米氮平与马普替林治疗难治性抑郁症的疗效和不良反应。方法:采用随机对照方法,分别给予米氮平和马普替林治疗,疗程6周。应用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表(CGI-SI)、和副反应量表(TESS)于疗前、疗后1,2,4,6,Weeks进行疗效和不良反应评定。结果:米氮平组治疗6周末HAMg)平均分值从31.5降至17.2分,HAMA平均分值从24.7降至14.4分。马普替林组分别从32.2降至22.7分和26.9降至21.5分。两组有效者分别为12例和4例。米氮平较马普替林见效快,副作用发生率低而轻微。结论:米氮平疗效优于马普替林,可用于治疗难治性抑郁症。Objective: To evaluate the efficacy and side effects of mirtazapine and maprotiline in the treatment of treatment - resistant depression (TRsD). Methods: The patients were randomly assigned into mirtazapine group and maprotiline group (control group). The efficacy and side effects were assessed with Hamilton depression scale (HAMD), Hamilton anxiety scale (HAMA), clinical global impression (CGI - SI) and the treatment emergent scale (TESS) before and after 1,2,4,6 weeks treatment respectively. Results: In mirtazapine group, the HAMD and HAMA scores decreased from 31. 5 to 17.2 and from 24. 7 to 14.4. And they decreased from 32.2 to 22.7 and from 26.9 to 21.5 in maprotiline group. The cases improved were respectively 12 and 4 in the two groups. Mirtazapine was more effective and had fewer side effects than Maprotiline in the treatment. Conclusions: The curative effect of Mirtazapine is better than that of Maprotiline in the treatment of treatment - resistant depression.

关 键 词：米氮平 马普替林 药和治疗 难治性抑郁症 不良反应 

分 类 号：R749.4[医药卫生—神经病学与精神病学] R971.4[医药卫生—临床医学]